Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
9.4 (1y: +64%)
Market Cap 12.87 B P/E(ttm)
Enterprise Value 16.86 B P/B 1.90
BSX- NYSE (USA)
Boston Scientific, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$9.40
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 0.049
BSX's Cash to Debt is ranked lower than
59% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. BSX: 0.049 )
BSX' s 10-Year Cash to Debt Range
Min: 0.04   Max: 0.69
Current: 0.05
0.04
0.69
Equity to Asset 0.4
BSX's Equity to Asset is ranked lower than
51% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. BSX: 0.4 )
BSX' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.57
Current: 0.4
0.4
0.57
F-Score: 4
Z-Score: -0.41
M-Score: -4.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -53.40
BSX's Operating margin (%) is ranked lower than
66% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BSX: -53.40 )
BSX' s 10-Year Operating margin (%) Range
Min: -53.4   Max: 28
Current: -53.4
-53.4
28
Net-margin (%) -56.1
BSX's Net-margin (%) is ranked lower than
65% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. BSX: -56.1 )
BSX' s 10-Year Net-margin (%) Range
Min: -56.1   Max: 18.9
Current: -56.1
-56.1
18.9
ROE (%) -59.2
BSX's ROE (%) is ranked lower than
68% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. BSX: -59.2 )
BSX' s 10-Year ROE (%) Range
Min: -59.2   Max: 26.4
Current: -59.2
-59.2
26.4
ROA (%) -23.7
BSX's ROA (%) is ranked lower than
64% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. BSX: -23.7 )
BSX' s 10-Year ROA (%) Range
Min: -23.7   Max: 13
Current: -23.7
-23.7
13
ROC (Joel Greenblatt) (%) -148.10
BSX's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. BSX: -148.10 )
BSX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -148.1   Max: 137.8
Current: -148.1
-148.1
137.8
Revenue Growth (%) -1.3
BSX's Revenue Growth (%) is ranked lower than
58% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BSX: -1.3 )
BSX' s 10-Year Revenue Growth (%) Range
Min: -8   Max: 20.8
Current: -1.3
-8
20.8
EBITDA Growth (%) 174.2
BSX's EBITDA Growth (%) is ranked higher than
100% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BSX: 174.2 )
BSX' s 10-Year EBITDA Growth (%) Range
Min: -60.8   Max: 174.2
Current: 174.2
-60.8
174.2
EPS Growth (%) 43.6
BSX's EPS Growth (%) is ranked higher than
98% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BSX: 43.6 )
BSX' s 10-Year EPS Growth (%) Range
Min: -29.9   Max: 43.6
Current: 43.6
-29.9
43.6
» BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BSX Guru Trades in Q2 2012

Ray Dalio 48,184 sh (New)
Jeremy Grantham 49,000 sh (New)
RS Investment Management 304,520 sh (New)
Diamond Hill Capital 12,883,647 sh (New)
Joel Greenblatt 109,009 sh (+971.66%)
Michael Price 601,300 sh (+140.52%)
Paul Tudor Jones 427,500 sh (+39.39%)
Jim Simons 2,594,545 sh (+23.07%)
Steven Cohen 560,427 sh (+4.41%)
Mario Gabelli 2,001,345 sh (+1.06%)
Vanguard Health Care Fund 46,800,000 sh (unchged)
Murray Stahl 22,439 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Bruce Kovner Sold Out
Dodge & Cox 107,555,351 sh (-2.28%)
Charles Brandes 20,449,360 sh (-6.99%)
PRIMECAP Management 54,689,410 sh (-11.58%)
Leon Cooperman 11,554,900 sh (-32.67%)
» More
Q3 2012

BSX Guru Trades in Q3 2012

Steven Cohen 2,859,586 sh (+410.25%)
Michael Price 1,500,000 sh (+149.46%)
Jeremy Grantham 99,900 sh (+103.88%)
Diamond Hill Capital 17,886,325 sh (+38.83%)
Leon Cooperman 14,331,900 sh (+24.03%)
Joel Greenblatt 135,038 sh (+23.88%)
Ray Dalio 55,284 sh (+14.74%)
Jim Simons 2,679,316 sh (+3.27%)
Mario Gabelli 2,004,805 sh (+0.17%)
Vanguard Health Care Fund 46,800,000 sh (unchged)
Murray Stahl 22,439 sh (unchged)
RS Investment Management Sold Out
PRIMECAP Management 51,979,927 sh (-4.95%)
Charles Brandes 19,377,180 sh (-5.24%)
Dodge & Cox 100,445,551 sh (-6.61%)
Paul Tudor Jones 51,800 sh (-87.88%)
» More
Q4 2012

BSX Guru Trades in Q4 2012

Pioneer Investments 36,103 sh (New)
Paul Tudor Jones 81,000 sh (+56.37%)
Mario Gabelli 2,418,305 sh (+20.63%)
Joel Greenblatt 156,437 sh (+15.85%)
Michael Price 1,700,000 sh (+13.33%)
Steven Cohen 2,902,530 sh (+1.5%)
Leon Cooperman 14,523,500 sh (+1.34%)
Vanguard Health Care Fund 46,600,000 sh (unchged)
Murray Stahl Sold Out
Vanguard Health Care Fund 46,600,000 sh (-0.43%)
Diamond Hill Capital 17,673,181 sh (-1.19%)
PRIMECAP Management 51,312,012 sh (-1.28%)
Charles Brandes 18,884,769 sh (-2.54%)
Dodge & Cox 97,535,051 sh (-2.9%)
Jim Simons 2,408,305 sh (-10.11%)
Ray Dalio 42,784 sh (-22.61%)
» More
Q1 2013

BSX Guru Trades in Q1 2013

Tom Russo 209 sh (New)
Jim Simons 8,400,805 sh (+248.83%)
Mario Gabelli 2,768,005 sh (+14.46%)
Leon Cooperman 16,473,300 sh (+13.43%)
Michael Price 1,700,000 sh (unchged)
Ray Dalio Sold Out
Pioneer Investments Sold Out
Dodge & Cox 95,996,823 sh (-1.58%)
Vanguard Health Care Fund 45,385,200 sh (-2.61%)
Diamond Hill Capital 17,198,821 sh (-2.68%)
PRIMECAP Management 49,253,619 sh (-4.01%)
Charles Brandes 16,909,816 sh (-10.46%)
Joel Greenblatt 124,980 sh (-20.11%)
Paul Tudor Jones 13,700 sh (-83.09%)
Steven Cohen 154,075 sh (-94.69%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2013-03-31 Add 13.43%0.24%$5.73 - $7.81 $ 9.432%16473300
Joel Greenblatt 2013-03-31 Reduce -20.11%0.01%$5.73 - $7.81 $ 9.432%124980
Ray Dalio 2013-03-31 Sold Out $5.73 - $7.81 $ 9.432%0
Michael Price 2012-12-31 Add 13.33%0.16%$5.07 - $5.82 $ 9.471%1700000
Mario Gabelli 2012-12-31 Add 20.63%0.02%$5.07 - $5.82 $ 9.471%2418305
Ray Dalio 2012-12-31 Reduce -22.61%$5.07 - $5.82 $ 9.471%42784
Michael Price 2012-09-30 Add 149.46%0.78%$4.99 - $5.82 $ 9.470%1500000
Leon Cooperman 2012-09-30 Add 24.03%0.31%$4.99 - $5.82 $ 9.470%14331900
Joel Greenblatt 2012-09-30 Add 23.88%0.01%$4.99 - $5.82 $ 9.470%135038
Leon Cooperman 2012-06-30 Reduce -32.67%0.65%$5.51 - $6.25 $ 9.460%11554900
Michael Price 2012-06-30 Add 140.52%0.29%$5.51 - $6.25 $ 9.460%601300
Joel Greenblatt 2012-06-30 Add 971.66%0.04%$5.51 - $6.25 $ 9.460%109009
Ray Dalio 2012-06-30 New Buy$5.51 - $6.25 $ 9.460%48184
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about Boston Scientific, Inc.

BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector
May 14, 2013
Leon Cooperman,Michael Price - BSX And ABMD Highlight Increased Insider Buying In The Medical Technology Sector
In the past week we saw an increase in insider buying coming from the health care industry. Last week GuruFocus reported 31 different insider buys coming from 19 different health care-based companies. These buys spanned across the sector from research and development labs to pharmaceutical companies. The following four companies are all a part of the medical supply sector of the health care industry. They represent significant insider buys coming from one or more directors or corporate executives. Read more...
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround
December 31, 2012
Leon Cooperman - Why Cooperman And Price Are Betting On Boston Scientific’s Turnaround
Boston Scientific(BSX) is a worldwide developer, manufacturer, and marketer of less-invasive medical devices used in a broad range of interventional medical specialties. The company has always prided itself on its continuing development of medical innovations aimed at raising standards, reducing costs, increasing efficiency, and providing faster recovery times for patients. Leon Cooperman and Michael Price have positions in Boston Scientific (BSX), one of the stock market’s most heart-breaking companies in the last few years. The company’s strengths are evident in its strong growth platform of products, a favorable price reflected in its low P/B ratio, a positive direction taken by new management, and aging populations around the world. Read more...

Ratios

vs
industry		 vs
history
P/B 1.90
BSX's P/B is ranked higher than
69% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BSX: 1.90 )
BSX' s 10-Year P/B Range
Min: 0.59   Max: 12.83
Current: 1.9
0.59
12.83
P/S 1.80
BSX's P/S is ranked higher than
67% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BSX: 1.80 )
BSX' s 10-Year P/S Range
Min: 1.02   Max: 10.34
Current: 1.8
1.02
10.34
PFCF 13.30
BSX's PFCF is ranked higher than
80% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 21.03 vs. BSX: 13.30 )
BSX' s 10-Year PFCF Range
Min: 7.25   Max: 192.5
Current: 13.3
7.25
192.5
EV-to-EBIT 18.2
BSX's EV-to-EBIT is ranked higher than
52% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. BSX: 18.2 )
BSX' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 128.8
Current: 18.2
8.8
128.8
Shiller P/E 111.9
BSX's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. BSX: 111.9 )
BSX' s 10-Year Shiller P/E Range
Min: 31   Max: 230
Current: 111.9
31
230

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 9.6
BSX's Price/Net Current Asset Value is ranked higher than
72% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. BSX: 9.6 )
BSX' s 10-Year Price/Net Current Asset Value Range
Min: 5.8   Max: 56.6
Current: 9.6
5.8
56.6
Price/DCF (Projected) 1.1
BSX's Price/DCF (Projected) is ranked higher than
84% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. BSX: 1.1 )
BSX' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 8.3
Current: 1.1
0.5
8.3
Price/Median PS Value 0.7
BSX's Price/Median PS Value is ranked higher than
88% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. BSX: 0.7 )
BSX' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 3.6
Current: 0.7
0.4
3.6
Earnings Yield (Greenblatt) 5.50
BSX's Earnings Yield (Greenblatt) is ranked higher than
79% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BSX: 5.50 )
BSX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 11.3
Current: 5.5
0.8
11.3
Forward Rate of Return (Yacktman) 3.8
BSX's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. BSX: 3.8 )
BSX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.5   Max: 51.1
Current: 3.8
-6.5
51.1

Business Description

Boston Scientific, Inc., is a worldwide developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women's Health, Neuromodulation, and Electrophysiology. The Company derives 33 percent of its sales from its Interventional Cardiology business, 27 percent of its sales from its CRM business, 16 percent of its sales from its Endoscopy business, 10 percent of its sales from its Peripheral Interventions business, six percent of its sales from its Urology/Women's Health business, four percent of its sales from its Neuromodulation business, and two percent of its sales from its Electrophysiology business. It develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardiac defibrillator systems used to detect and treat abnormally fast heart rhythms that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator systems used to treat heart failure; and Implantable pacemaker systems used to manage slow or irregular heart rhythms, including implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure. Within the Company's Electrophysiology business, it offers medical devices for the diagnosis and treatment of cardiac arrhythmias. Included in its product offerings are RF generators, intracardiac ultrasound and steerable ablation catheters, and diagnostic catheters. The Company's main competitors include Abbott Laboratories; Medtronic, Inc.; St. Jude Medical, Inc.; and Johnson & Johnson as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. It also faces competition from non-medical device companies, such as pharmaceutical companies, which may offer alternative therapies for disease states intended to be treated using its products. The medical devices that the Company manufactures and markets are subject to regulation by numerous regulatory bodies, including the FDA and comparable international regulatory agencies.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:BSX.Germany
» More Articles for BSX

Headlines

Articles On GuruFocus.com
comment on BSX May 22 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Three Key Forces That Drive up Stock Prices Mar 25 2013 
comment on BSX Feb 03 2013 
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround Dec 31 2012 
Boston Scientific's September Earnings Reflect Aggressive Accounting Oct 24 2012 
comment on BSX Sep 20 2012 
Boston Scientific's Interesting Expenses Sep 11 2012 
Weekly Top Insider Buys: WMB, ADM, VNO, FITB, BSX Aug 13 2012 
Weekly Top Insider Buys: GE, FDX, ADM, BSX, TKR Aug 06 2012 

More From Our Partners
BSX Commences U.S. INTREPID Trial - Analyst Blog Jun 18 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK